{
    "doi": "https://doi.org/10.1182/blood-2021-146848",
    "article_title": "Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter \"Real-World\" Study ",
    "article_date": "November 5, 2021",
    "session_type": "642.Chronic Lymphocytic Leukemia: Clinical and Epidemiological",
    "abstract_text": "Introduction: In previously untreated patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus rituximab improved progression-free survival (PFS) and overall survival (OS) compared to the standard fludarabine, cyclophosphamide and rituximab (FCR) chemoimmunotherapeutic regimen, based on the results of the phase III ECOG-E1912 trial. The improvement in PFS with ibrutinib plus rituximab was observed in patients with unmutated immunoglobulin heavy chain variable region gene (IGHV) but not in those with an IGHV mutated profile. However, the efficacy of ibrutinib compared to FCR has not yet been investigated in the real-world setting. Methods : A multi-center retrospective \"real-world\" study to compare the efficacy of front-line ibrutinib monotherapy versus standard FCR in patients with CLL. Demographic and clinical data of the FCR cohort were retrieved from the Israeli CLL Study Group database and of the ibrutinib from the Italian multicenter \"Campus CLL\" network and the CLL database of the department of hematology at the Sourasky Medical Center. Patients with a documented del(17p) or those who are participating in clinical trials were excluded. In order to fit both treatment samples, the maximum follow-up was censored at 48 months. IBM SPSS Statistics was used to analyze PFS and OS by Kaplan Meier Estimator, Log-Rank test and Cox Regression. In order to control for differences in patients' characteristics, the inverse probability of treatment weighting (IPTW) method with stabilized weights and truncation of 5% extreme score was applied by R. Results : A total of 235 patients who had been front-line treated with either FCR (n=136, 57.9%) or ibrutinib (n=99, 42.1%) were included (Table 1). Most patients were males (n=160, 68.1%), had an unmutated IGHV status (n=115, 70.6%) and were Binet stage B/C (n=191, 83.8%). By FISH, the most frequent abnormality was del(11q) (n=45, 23.1%) followed by trisomy12 (n=34, 17.4%) and del(13q) (n=43, 22.1%). Median time to first treatment was 29.4 months (IQR, 11.9-56.2), and it was not significantly different between ibrutinib (median=24.9 months, IQR 10.3-46.6) and FCR (median=34.0 months, IQR 13.8-60.1; p=0.101). Patients treated with FCR were younger than those treated with ibrutinib (median=58.4 years vs. 71.9 years; p65 years (n=100, 3-year PFS 89.4% vs. 53.1%; HR=3.9, 95% CI [1.6-9.9], p=0.002), Binet stage B/C (3-year PFS: 90.5% vs. 67.8%; HR=3.5, 95% CI [1.7-7.5], p<0.001) and unmutated IGHV (3-year PFS: 83.0% vs. 78.0%; HR=5.8, 95% CI [2.4-14.5], p<0.001). Among mutated IGHV patients the PFS was not significantly different between ibrutinib and FCR (3-year PFS: 83.0% vs. 78.0%; HR=1.2, 95% CI [0.3, 4.5]; P=0.795). In multivariate analysis (Table 2), only FCR was an independent predictor of decreased PFS (HR=5.1, 95% CI [1.8, 14.3], p=0.002). OS was also better with ibrutinib than with FCR, with a 3-year OS of 96.8% vs. 87.5%, respectively (HR=3.52, 95% CI [1.04-11.92], p=0.031) (Figure 2). Using IPTW, both PFS and OS were still superior with ibrutinib compared to FCR (HR=0.2, 95% CI 0.1-0.5, p<0.001 and HR=0.2, 95% CI [0.1-0.7], p=0.008, respectively). Conclusions : In a real-world setting, front-line treatment with ibrutinib improves PFS and OS in patients with CLL. Similar to the results of the phase III ECOG-E1912 trial, the improvement in PFS was preferentially observed in patients with unmutated IGHV. Figure 1 View large Download slide Figure 1 View large Download slide  Close modal Disclosures Herishanu:  AbbVie: Honoraria, Research Funding; Janssen: Honoraria; Roche: Honoraria; Medison: Honoraria. Goldschmidt:  AbbVie: Consultancy, Research Funding. Fineman:  AbbVie: Research Funding. Mauro:  Roche: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria, Speakers Bureau; Astra Zeneca: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Tskeda: Consultancy, Honoraria. Reda:  Abbvie: Consultancy; Astra Zeneca: Consultancy; Beigene: Consultancy; Janssen: Consultancy. Ruchlemer:  AbbVie: Consultancy, Honoraria, Research Funding. Sportoletti:  AstraZeneca: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Laurenti:  AstraZeneca: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Gilead: Honoraria; Roche: Honoraria, Research Funding; Janssen: Consultancy, Honoraria; BeiGene: Honoraria. Shvidel:  AbbVie: Honoraria, Research Funding. Coscia:  Janssen: Honoraria, Other, Research Funding; Gilead: Honoraria; AbbVie: Honoraria, Other; AstraZeneca: Honoraria. Tadmor:  Janssen: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. Varettoni:  AstraZeneca: Membership on an entity's Board of Directors or advisory committees; beigene: Membership on an entity's Board of Directors or advisory committees; janssen: Membership on an entity's Board of Directors or advisory committees; roche: Membership on an entity's Board of Directors or advisory committees. Aviv:  AbbVie: Honoraria, Research Funding. Murru:  Abbvie: Consultancy, Honoraria, Other: travel and accommodation; Janssen: Consultancy, Honoraria. Rossi:  Abbvie: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Verastem: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Cellestia: Honoraria, Research Funding. Gaidano:  Incyte: Membership on an entity's Board of Directors or advisory committees; Beigene: Membership on an entity's Board of Directors or advisory committees; Astrazeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Cuneo:  AbbVie: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau. Gattei:  abbVie: Research Funding; Janssen: Research Funding; Menarini: Research Funding.",
    "author_names": [
        "Yair Herishanu",
        "Shai Levi",
        "Neta Goldschmidt",
        "Fortunato Morabito",
        "Osnat Bairey",
        "Giovanni Del Poeta",
        "Tomer Ziv Baran",
        "Riva Fineman",
        "Francesca Romana Mauro",
        "Odit Gutwein",
        "Gianluigi Reda",
        "Rosa Ruchlemer",
        "Paolo Sportoletti",
        "Luca Laurenti",
        "Lev Shvidel",
        "Marta Coscia",
        "Tamar Tadmor",
        "Marzia Varettoni",
        "Ariel Aviv",
        "Roberta Murru",
        "Andrei Breaster",
        "Yotam Bronstein",
        "Annalisa Chiarenza",
        "Andrea Visentin",
        "Daniela Pietrasanta",
        "Giacomo Loseto",
        "Antonella Zucchetto",
        "Riccardo Bomben",
        "Jacopo Olivieri",
        "Antonino Neri",
        "Davide Rossi",
        "Gianluca Gaidano",
        "Livio Trentin",
        "Robin Foa",
        "Antonio Cuneo",
        "Valter Gattei",
        "Massimo Gentile"
    ],
    "author_dict_list": [
        {
            "author_name": "Yair Herishanu",
            "author_affiliations": [
                "Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Shai Levi",
            "author_affiliations": [
                "Hematology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Neta Goldschmidt",
            "author_affiliations": [
                "Hematology, Hadassah University Hospital Ein Kerem, Jerusalem, Israel"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fortunato Morabito",
            "author_affiliations": [
                "Hematology and Bone Marrow Transplant Unit, Hemato-Oncology Department, Augusta Victoria Hospital, Jerusalem, Israel",
                "Biothechnology Research Unit, AO of Cosenza, Cosenza, ITA"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Osnat Bairey",
            "author_affiliations": [
                "Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giovanni Del Poeta",
            "author_affiliations": [
                "Hematology, Department of Biomedicine and Prevention, University Tor Vergata, Roma, Italy"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Tomer Ziv Baran",
            "author_affiliations": [
                "School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University., Tel-Aviv, Israel"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Riva Fineman",
            "author_affiliations": [
                "Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesca Romana Mauro",
            "author_affiliations": [
                "Hematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Roma, Italy"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Odit Gutwein",
            "author_affiliations": [
                "Assaf Ha'Rofeh, Tsrifin, Israel"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gianluigi Reda",
            "author_affiliations": [
                "U.O.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rosa Ruchlemer",
            "author_affiliations": [
                "Department of Hematology, Shaare-Zedek Medical Center, affiliated with the Hebrew University Medical School, Jerusalem, Israel"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paolo Sportoletti",
            "author_affiliations": [
                "Institute of Hematology and Center of Hemato-Oncology Research (CREO), University of Perugia, Perugia, Italy"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Luca Laurenti",
            "author_affiliations": [
                "Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lev Shvidel",
            "author_affiliations": [
                "Department of Hematology, Kaplan Medical Center, Rehovot, Israel"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marta Coscia",
            "author_affiliations": [
                "Department of Molecular Biotechnology and Health Sciences and Division of Hematology, University of Torino, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Tamar Tadmor",
            "author_affiliations": [
                "Hematology Unit, Bnai Zion Medical Center, Haifa, Israel"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marzia Varettoni",
            "author_affiliations": [
                "Division of Hematology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ariel Aviv",
            "author_affiliations": [
                "Department of Hematology, HaEmek Medical Center, Afula, Israel"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roberta Murru",
            "author_affiliations": [
                "SC Ematologia e CTMO, Ospedale Oncologico A. Businco, ARNAS \"G. Brotzu\", Cagliari, Italy"
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrei Breaster",
            "author_affiliations": [
                "Galilee Medical Center, Nahariya, Israel"
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Yotam Bronstein",
            "author_affiliations": [
                "Internal Medicine Division, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Annalisa Chiarenza",
            "author_affiliations": [
                "U.O.C. Ematologia, A.O.U. Policlinico \"G. Rodolico - S. Marco\", Catania, Italy"
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Visentin",
            "author_affiliations": [
                "Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy"
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Daniela Pietrasanta",
            "author_affiliations": [
                "Division of Hematology, Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo, Alessandria, Italy"
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giacomo Loseto",
            "author_affiliations": [
                "Division of Hematology, IRCCS Ospedale Oncologico Giovanni Paolo II, Bari, Italy"
            ],
            "author_rank": 26,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonella Zucchetto",
            "author_affiliations": [
                "Clinical and Experimental Onco-Hematology Unit, Centro Di Riferimento Oncologico, Aviano, Italy"
            ],
            "author_rank": 27,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Riccardo Bomben",
            "author_affiliations": [
                "Clinical and Experimental Onco-Hematology Unit, Centro Di Riferimento Oncologico, Aviano, ITA"
            ],
            "author_rank": 28,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jacopo Olivieri",
            "author_affiliations": [
                "Clinica Ematologica, Centro Trapianti e Terapie Cellulari \"Carlo Melzi\", Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy"
            ],
            "author_rank": 29,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonino Neri",
            "author_affiliations": [
                "BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"
            ],
            "author_rank": 30,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Davide Rossi",
            "author_affiliations": [
                "Amedeo Avorgadro Univ. of Eastern Piedmont, Bellinzona, Italy"
            ],
            "author_rank": 31,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gianluca Gaidano",
            "author_affiliations": [
                "Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy"
            ],
            "author_rank": 32,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Livio Trentin",
            "author_affiliations": [
                "Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy"
            ],
            "author_rank": 33,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Robin Foa",
            "author_affiliations": [
                "Hematology, Sapienza University of Rome, Rome, Italy"
            ],
            "author_rank": 34,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Cuneo",
            "author_affiliations": [
                "Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy"
            ],
            "author_rank": 35,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Valter Gattei",
            "author_affiliations": [
                "Clinical and Experimental Onco-Hematology Unit, Centro Di Riferimento Oncologico, Aviano, Italy"
            ],
            "author_rank": 36,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Massimo Gentile",
            "author_affiliations": [
                "UOC Ematologia AO di Cosenza, Presidio Ospedaliero Annunziata, Cosenza, Italy"
            ],
            "author_rank": 37,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-21T18:44:05",
    "is_scraped": "1"
}